GlassScriptPhysician profile
Andrea M Mcknight
NPI 1295961456
$4,370.60
in general payments reported to CMS, 2019-2025
30 companies · $533 in 2025
The $533 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $145 · 2021: $1,335 · 2022: $441 · 2023: $515 · 2024: $526 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.91 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,241.46 | 2021 | |
| Pfizer INC. | $381.61 | 2019-2025 | |
| Astellas Pharma US INC | $309.74 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $266.07 | 2019-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $216.19 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $183.88 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.41 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $172.61 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $155.80 | 2019-2025 | Bexsero, Shingrix, Pediarix |
| Amarin Pharma, INC. | $145.90 | 2019-2021 | |
| Dexcom, INC. | $133.26 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $122.04 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $91.02 | 2024-2025 | Spravato |
| Merck Sharp & Dohme LLC | $83.39 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Sumitomo Pharma America, INC. | $80.99 | 2023-2025 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $71.18 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $61.44 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.11 | 2022-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $49.06 | 2025 | Auvelity |
| Organon LLC | $46.62 | 2023-2025 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $45.74 | 2019-2022 | |
| Amgen INC. | $43.84 | 2019-2023 | Repatha, Otezla |
| Supernus Pharmaceuticals, INC. | $40.43 | 2019 | |
| Dynavax Technologies Corporation | $36.29 | 2022-2024 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $34.87 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.79 | 2023-2024 | Quviviq |
| Sanofi Pasteur INC. | $28.28 | 2019 | |
| Medtronic, INC. | $26.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.22 | 2025 | |
| Vivus LLC | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Mcknight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.